Prostate Cancer (PCa) is the second most commonly diagnosed cancer in men worldwide.
Although increased expression of prostate-specific antigen (PSA) is an effective indicator for …

PURPOSE: Prostate Cancer (PCa) represents the second most frequent type of tumor in
men worldwide. Incidence increases with patient age and represents the most important risk …

Prostate cancer (PC) is a leading cause of morbidity and mortality among men worldwide.
Molecular biomarkers work in conjunction with existing clinicopathologic tools to help …

Following the introduction of routine Prostate Specific Antigen (PSA) screening in the early
1990′ s, Prostate Cancer (PCa) is often detected at an early stage. There are also a …

Prostate cancer (PCa) is the most common cancer diagnosis and the second most common
cause of cancer‐related deaths in men. Currently, serum prostate‐specific antigen (PSA) is …

Prostate cancer affects 3 in 10 men over the age of 50 years, and, unfortunately, the clinical
course of the disease is poorly predicted. At present, there is no means that can distinguish …

Prostate cancer is one of the most commonly diagnosed malignancy and the fifth leading
cause of cancer mortality in men. Despite the broad use of prostate-specific antigen test that …

Despite advances in molecular medicine, genomics, proteomics and translational research,
prostate cancer remains the second most common cause of cancer-related mortality for men …

Introduction: Although prostate cancer constitutes one of the most important, death-related
diseases in the male population, there is still a need for identification of sensitive biomarkers …

Worldwide, prostate cancer (PC) is the second-most-frequently diagnosed male cancer and
the fifth-most-common cause of all cancer-related deaths. Suspicion of PC in a patient is …